WASHINGTON — The budget deal announced in the Senate on Wednesday contained a provision surprising to drug companies and Medicare beneficiaries alike: a sooner-than-expected change to the program’s “donut hole” coverage gap.
The provision included in the budget plan would mean a sizable hit to the pharmaceutical industry. It would move from 2020 to 2019 a requirement that drug makers pick up a larger portion of costs for their medicines for Part D beneficiaries who reach the so-called “donut hole” — a gap in Medicare coverage where beneficiaries often have to pay eye-watering drug prices out of pocket up to a certain dollar amount.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Authors
